1) Publication number:

0 306 347 A3

12

EUROPEAN PATENT APPLICATION

- (21) Application number: 88308187.9
- (1) Int. Cl.5: A61K 31/70

- ② Date of filing: 05.09.88
- Priority: 04.09.87 US 93523
 07.07.88 US 220765
 29.08.88 US 237019
- ② Date of publication of application: 08.03.89 Bulletin 89/10
- Designated Contracting States:

 AT BE CH DE ES FR GB GR IT LI LU NL SE
- Date of deferred publication of the search report:
 03.10.90 Bulletin 90/40
- Applicant: HEM RESEARCH, INC. 12280 Wilkins Avenue P.O. Box 2245 Rockville, MD 20852(US)
- Inventor: Carter, William A.
 1, Jaine Lane
 Birchrunville Pennsylvania 19421(US)
- Representative: Hallybone, Huw George et al CARPMAELS AND RANSFORD 43
 Bloomsbury Square
 London WC1A 2RA(GB)
- Diagnosis and treatment of double-stranded RNA deficiency states.
- The use of a double-stranded RNA (dsRNA) for the manufacture of medicament for the treatment of a dsRNA deficient disease state other than an HiV infection or a cancer. Specific such disease states include chronic fatigue syndrome and hepatitus infections.

EP 0 306 347 A3



EUROPEAN SEARCH REPORT

EP 88 30 8187

Cotono	Citation of document with in	dication, where appropriate,	Relevant	CLASSIFICATION OF TH
Category	of relevant pas	SE See	to ctains	APPLICATION (Int. CL4)
E	EP-A-0 299 745 (HER * Column 5, lines 12		1-7	A 61 K 31/70
D,E	EP-A-0 285 263 (HEM RESEARCH, INC.) * As a whole *		1-7	
E	EP-A-0 308 066 (HER * As a whole, espect 22-39; claims *		1-7	
D,X	THE LANCET, 6th June pages 1286-1292; W./ "Clinical, immunology virological effects mismatched double-singular patients with AIDS complex" * The whole article	A. CARTER et al.: gical, and of ampligen, a tranded RNA, in or AIDS-related	1-7	
D,X	EP-A-0 213 921 (HEM RESEARCH, INC.) * The whole document *			TECHNICAL FIELDS SEARCHED (Int. CL4)
P,X	PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, New orleans, Louisiana, 22nd-24th May 1988, vol. 7, March 1988, page 2, abstract no. A6; D.R. STRAYER et al.: "Clinical improvement and immunological/virological effects of ampligen therapy in ARC/pre-ARC patients" * Abstract *		1,3	A 61 K C 07 H C 12 Q
		-/-		
	The present search report has be			
TH	Place of search E HAGUE	Data of completion of the second 11-07-1990		RSTER W.K.
X : par Y : par doo A : tec	ticularly relevant if taken alone ticularly relevant if combined with and cument of the same category hadogical background	E: earlier par after the f ther D: document L: document	cited in the application cited for other reason:	dished os, or
THE HAGUE CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document		T: theory or E: enrier par after the father D: document L: document	principle underlying the ant document, but pul- lling date cited in the application	e invention dished on, or

EUROPEAN SEARCH REPORT

Application Number

EP 88 30 8187

Category	Citation of document with in of relevant pas	dication, where appropriate, sages	Relevant to claim	CLASSIFICATION OF TH APPLICATION (Int. Cl. 4)
X	PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, Atlanta, Georgia, 17th-19th May 1987, vol. 6, March 1987, page 2, abstract no. A8; W.A. CARTER et al.: "Clinical improvement of patients with HIV-related immune dysfunction on mismatched dsRNA (ampligen) therapy" * Abstract *		1,3	•
X	JOURNAL OF BIOLOGICA MODIFIERS, vol. 4, 1 Raven Press, New Yor et al.: "Clinical st (Mismatched double-s * Page 673 *	1985, pages 699-675, k, US; I. BRODSKY Sudies with ampligen	1,3	
D,X	AIDS RESEARCH, vol. pages 127-131, Mary J.M. WU et al.: "Dia the determiation of interferon-induced edecreased 2',5'-olig dependent binding praids patient lymphoc	Ann Liebert Inc.; ignostic value of an inzyme activity: joadenylate rotein activity in cytes"	1-7	TECHNICAL FIELDS SEARCHED (Int. CL4)
D,Y	* The whole article * NUCLEIC ACIDS RESEARCH, vol. 9, no. 7, 1981, pages 1571-1581, IRL Press, Ltd, Londen, GB; D.H. WRESCHNER et al.: "Ribosomal RNA cleavage, nuclease activation and 2-5A (ppp(A2'p)nA) in interferon-treated cells" * The whole article * -/-		1-7	
	The present search report has been Place of search	en drawn up for all claims Date of completion of the search		Excessive:
THE	HAGUE	11-07-1990		RSTER W.K.
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background		E : earlier pater after the fili her D : document ci	nciple underlying the t document, but publing date ted in the application ted for other reasons	ished on, or
O : POT	-written disclosure	A company of t	he same patent famil	

EUROPEAN SEARCH REPORT

Application Number

EP 88 30 8187

Category	Citation of document with of relevant p	indication, where apprepriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
D,Y	CELL, vol. 43, 1989 J.N. ZULLO et al.: growth factor and c	pages 793-800; "Platelet-derived iouble-stranded stimulate expression in 3T3 cells"	1-7	
D,Y	EUROPEAN J. BIOCHEM., vol. 143, 1984, pages 165-174; P.J. CAYLEY et al.: "Activation of the ppp(A2'p)nA system in interferon-treated, Herpes simplex virus-infected cells and evidence for novel inhibitors of the ppp(A2'p)nA-dependent RNase" * The whole article *		1-7	
A	ARCH. INTERN. MED., 1970, pages 109-124 "Double-stranded RN prevention of viral * The whole documen	k; M.R. HILLEMAN: As (poly I:C) in the infections	1-7	TECHNICAL FIELDS
D,A	PROC. NATL. ACAD. SCI. USA, vol. 84, February 1987, pages 658-662; A. DE BENEDETTI et al.: "Loss of (2'-5')oligoadenylate synthetase activity by production of antisense RNA results in lack of protection by interferon from viral infections" * The whole document *		1-7	SEARCHED (Int. Cl.4)
	The present search report has i	peen drawn up for all claims Date of completion of the search		Bossier
THE	HAGUE	11-07-1990		STER W.K.
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document		NTS T: theory or pr E: earlier pater after the fill other D: document c	T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons	
		å : member of 1	& : member of the same patent family, corresponding document	